Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Fulcrum Therapeutics, Inc. (FULC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.77+0.80%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for FULC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
maintain cash and equivalents near $350 million | It has about $352 million in cash to support operations. | Intact | cash falls below $300 million by end 2026 | Cash and cash equivalents: $48.466M FY2026-Q2; GAAP. Published target: >= $350 million cash and equivalents. Target period is not explicitly aligned with this observation. Date unavailable48,466,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
FULC is a high-risk, loss-making biotechnology company in a sector with a supportive backdrop. Its long-term thesis is in a watch state: weak recent performance and volatile management execution leave the outcome dependent on the strategic review and preservation of cash.
The valuation evidence suggests FULC is cheap versus peers, but confidence in that comparison is low. The expectations gap is negative, and the priced-in assessment is marked justified, with no fragility signals; this does not remove the business risks.
Near term, restructuring is intended to lower operating costs, while management expects cash to fund operations into 2029. The pociredir program was discontinued after FDA concerns about malignancy risks, and recent financial performance is weak; the next call and any guidance change are key risks.
Over the next few quarters, the thesis hinges on whether the strategic review identifies a viable path and whether cost cuts help preserve the stated cash runway. A guidance cut or further weakening jobs data could weigh on the business backdrop, while continued strength from major healthcare companies could support sector momentum.
For the 1-to-3-year view, FULC remains a fragile, loss-making story with cash runway and a strategic review as the main supports, set against execution and near-term business risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Fulcrum Therapeutics, Inc.'s published investment case. The stated target is engage and progress in strategic alternatives review. |
| Recovered |
| no meaningful progress in strategic alternatives review by mid 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
reduce workforce by approximately 85% | A primary condition in Fulcrum Therapeutics, Inc.'s published investment case. The stated target is reduce workforce by ~85%. | Intact | workforce reduction falls short of ~85% by mid 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.67 → $-0.12 · observed estimates
$0.36B → $0.36B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.67 | $361,240,000 | 6 / 6 |
| 2026-07-25 | $-0.58 | $0 | 7 / 6 |
| 2026-07-26 | $-0.58 | $0 | 7 / 6 |
| 2026-07-27 | $-0.67 | $361,240,000 | 6 / 6 |
| 2026-07-28 | $-0.67 | $361,240,000 | 6 / 6 |
| 2026-07-29 | $-0.58 | $0 | 7 / 6 |
| 2026-07-30 | $-0.67 | $361,240,000 | 6 / 6 |
| 2026-07-31 | $-0.58 | $0 | 7 / 6 |
| 2026-08-01 | $-0.67 | $361,240,000 | 6 / 6 |
| 2026-08-02 | $-0.58 | $0 | 7 / 6 |
| 2026-08-03 | $-0.58 | $0 | 7 / 6 |
| 2026-08-04 | $-0.58 | $0 | 7 / 6 |
| 2026-08-05 | $-0.53 | $0 | 7 / 5 |
| 2026-08-06 | $-0.53 | $0 | 7 / 5 |
| 2026-08-07 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-08 | $-0.53 | $0 | 7 / 5 |
| 2026-08-09 | $-0.53 | $0 | 7 / 5 |
| 2026-08-10 | $-0.53 | $0 | 7 / 5 |
| 2026-08-12 | $-0.49 | $0 | 7 / 5 |
| 2026-08-13 | $-0.49 | $0 | 7 / 5 |
| 2026-08-14 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-15 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-16 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-17 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-18 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-19 | $-0.62 | $361,240,000 | 6 / 6 |
| 2026-08-20 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-21 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-22 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-23 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-24 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-25 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-26 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-27 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-28 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-29 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-30 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-08-31 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-01 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-02 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-03 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-04 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-05 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-06 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-07 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-08 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-09 | $-0.34 | $361,240,000 | 6 / 5 |
| 2026-09-10 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-11 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-12 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-13 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-14 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-15 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-16 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-17 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-18 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-19 | $-0.12 | $361,240,000 | 6 / 5 |
| 2026-09-20 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-09-21 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-09-22 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-09-23 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-09-24 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-09-25 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-09-26 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-09-27 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-09-28 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-09-29 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-09-30 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-01 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-02 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-03 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-04 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-05 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-06 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-07 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-08 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-09 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-10 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-11 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-12 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-13 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-14 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-15 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-16 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-17 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-18 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-19 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-20 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-21 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-22 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-23 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-24 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-25 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-26 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-27 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-28 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-29 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-30 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-10-31 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-11-01 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-11-02 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-11-03 | $-0.12 | $361,240,000 | 5 / 4 |
| 2026-11-04 | $-0.12 | $361,240,000 | 5 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 4 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.